Nonalcoholic Fatty Liver Disease and Thrombocytopenia III: Its Association With Insulin Resistance

López-Trujillo, Miguel Antonio; Olivares-Gazca, Jesús Mauricio; Cantero-Fortiz, Yahveth; García-Navarrete, Yarely Itzayana; Cruz-Mora, Antonio; Olivares‐Gazca, Juan Carlos; Murrieta-Álvarez, Iván; León‐Peña, Andrés A.; Ruíz-Delgado, Guillermo J.; Ruíz‐Argüelles, Guillermo J.

doi:10.1177/1076029619888694

Cited by 11 publications

(13 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Quantose M Q is a test that can predict the progression from normal glucose tolerance to impaired glucose tolerance and, finally, diabetes [36]. Scores above 63 are indicative of IR [51].…”

Section: Quantification Of 2hbmentioning

confidence: 99%

“…Furthermore, Ref. [51] showed that the mean Quantose M Q score was elevated in IR patients. The author explored the reason for that increasing in the score, pointing to non-alcoholic fatty liver disease as a possible cause, which involves NAFLD (involved in oxidative stress, including a set of molecules such as adipokines, chemokine and proinflammatory cytokines).…”

Section: Quantose M Qmentioning

confidence: 99%

See 1 more Smart Citation

Which Role Plays 2-Hydroxybutyric Acid on Insulin Resistance?

et al. 2021

View full text Add to dashboard Cite

Type 2 Diabetes Mellitus (T2D) is defined as a chronic condition caused by beta cell loss and/or dysfunction and insulin resistance (IR). (1) Background: The discovering of novel biomarkers capable of identifying T2D and other metabolic disorders associated with IR in a timely and accurate way is critical. In this review, 2-hydroxybutyric acid (2HB) is presented as that upheaval biomarker with an unexplored potential ahead. Due to the activation of other metabolic pathways during IR, 2HB is synthesized as a coproduct of protein metabolism, being the progression of IR intrinsically related to the increasing of 2HB levels. Hence, the focus of this review will be on the 2HB metabolite and its involvement in glucose homeostasis. (2) Methods: A literature review was conducted, which comprised an examination of publications from different databases that had been published over the previous ten years. (3) Results: A total of 19 articles fulfilled the intended set of criteria. The use of 2HB as an early indicator of IR was separated into subjects based on the number of analytes examined simultaneously. In terms of the association between 2HB and IR, it has been established that increasing 2HB levels can predict the development of IR. (4) Conclusions: Thus, 2HB has demonstrated considerable promise as a clinical monitoring molecule, not only as an IR biomarker, but also for disease follow-up throughout IR treatment.

show abstract

“…Quantose M Q is a test that can predict the progression from normal glucose tolerance to impaired glucose tolerance and, finally, diabetes [36]. Scores above 63 are indicative of IR [51].…”

Section: Quantification Of 2hbmentioning

confidence: 99%

Section: Quantose M Qmentioning

confidence: 99%

Which Role Plays 2-Hydroxybutyric Acid on Insulin Resistance?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Strictly speaking, the cause of the thrombocytopenia we observe in NAFLD is unknown, but several explanations have been offered, such as a certain degree of hypersplenism, bone marrow hypoplasia, reduced peripheral blood cell survival, thrombopoietin deficiency, among others. [1][2][3][4][5][6] Since hypersplenism may lead into granulocytopenia, we also explored the association of NAFLD, granulocytopenia, and thrombocytopenia and found that there is a significant association between these variables, thus suggesting that hypersplenism may somehow be involved in the origin of the cytopenias observed in people with NAFLD. 4 As a result of the studies that have been conducted in this condition, we have learned that the salient features of the NAFLD-associated thrombocytopenia are: (1) it presents in around one-fifth of patients, depending on the method employed to define the liver damage; (2) it is associated with excess weight; (3) it is usually mild, with platelet count above 40 Â 10 9 /L; (4) it is not associated to mucocutaneous bleeding; and (5) it does not need specific treatment to improve the platelet count.…”

mentioning

confidence: 99%

“…Since 2014, we have been conducting prospective studies to assess the presence of thrombocytopenia (less than 100 Â 10 9 /L platelets) in persons with NAFLD without overt liver cirrhosis. [1][2][3][4] The concept was initially entertained by Dasanu et al in 2010. 5 To define the presence of NAFLD, several methods can be employed: liver biopsy, serologic determinations (Fibromax), and liver transient elastography (TE/Fibroscan).…”

mentioning

confidence: 99%

“…6 Since NAFLD is the hepatic component of insulin resistance, we assessed the association of thrombocytopenia and insulin resistance and found that, in the absence of NAFLD, insulin resistance by itself is not associated with thrombocytopenia. 3 It seems that changes in the intrahepatic circulation and/or structure are needed to induce the drop in platelet count. Strictly speaking, the cause of the thrombocytopenia we observe in NAFLD is unknown, but several explanations have been offered, such as a certain degree of hypersplenism, bone marrow hypoplasia, reduced peripheral blood cell survival, thrombopoietin deficiency, among others.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Démonstration de Faisabilité: Nonalcoholic Fatty Liver Disease May Cause Thrombocytopenia

Ruíz‐Argüelles

2021

Semin Thromb Hemost

Self Cite

View full text Add to dashboard Cite

show abstract

Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis

Ghandian¹,

Thapa²,

Garikipati³

et al. 2022

JGH Open

View full text Add to dashboard Cite

Background: Non-alcoholic fatty liver (NAFL) can progress to the severe subtype non-alcoholic steatohepatitis (NASH) and/or fibrosis, which are associated with increased morbidity, mortality, and healthcare costs. Current machine learning studies detect NASH; however, this study is unique in predicting the progression of NAFL patients to NASH or fibrosis. Aim: To utilize clinical information from NAFL-diagnosed patients to predict the likelihood of progression to NASH or fibrosis. Methods: Data were collected from electronic health records of patients receiving a first-time NAFL diagnosis. A gradient boosted machine learning algorithm (XGBoost) as well as logistic regression (LR) and multi-layer perceptron (MLP) models were developed. A five-fold cross-validation grid search was utilized for hyperparameter optimization of variables, including maximum tree depth, learning rate, and number of estimators. Predictions of patients likely to progress to NASH or fibrosis within 4 years of initial NAFL diagnosis were made using demographic features, vital signs, and laboratory measurements. Results: The XGBoost algorithm achieved area under the receiver operating characteristic (AUROC) values of 0.79 for prediction of progression to NASH and 0.87 for fibrosis on both hold-out and external validation test sets. The XGBoost algorithm outperformed the LR and MLP models for both NASH and fibrosis prediction on all metrics. Conclusion: It is possible to accurately identify newly diagnosed NAFL patients at high risk of progression to NASH or fibrosis. Early identification of these patients may allow for increased clinical monitoring, more aggressive preventative measures to slow the progression of NAFL and fibrosis, and efficient clinical trial enrollment.

show abstract

Nonalcoholic Fatty Liver Disease and Thrombocytopenia III: Its Association With Insulin Resistance

Cited by 11 publications

References 13 publications

Which Role Plays 2-Hydroxybutyric Acid on Insulin Resistance?

Which Role Plays 2-Hydroxybutyric Acid on Insulin Resistance?

Démonstration de Faisabilité: Nonalcoholic Fatty Liver Disease May Cause Thrombocytopenia

Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis

Contact Info

Product

Resources

About